Corporate News
Bayer CropScience completes acquisition of biotech company Athenix Corp.
Purchase price of USD 365 million plus milestones more
Bayer back on the uptrend
HealthCare again strong – weak quarter at CropScience – MaterialScience substantially improved / Group sales EUR 7,392 million (minus 7.0 percent) / EBITDA before special items EUR 1,499 million... more
Bayer Early Excellence in Science Award 2009: EUR 30,000 for young research scientists (copy 1)
Dr. Jürgen Groll (RWTH Aachen) awarded prize in the “Materials” field / Dr. Noriyuki Nishimura (University of California, San Diego, United States) honored in the “Biology” category / Dr. Tobias... more
Bayer CropScience first to sequence the entire genome of rapeseed/canola
Milestone will result in speeding up of research and breeding programs more
Children’s pictures challenge climate change
Bayer and UNEP and other partners present prizes at the environment conference in Korea to children from all over the world who painted pictures on the subject of “Climate Change: Our Challenge” /... more
Bayer CropScience acquires US biotech company Athenix Corp.
Monheim, August 19, 2009 – Bayer CropScience announced today that it has entered into an agreement to purchase Athenix Corp., a privately-held independent biotechnology company headquartered in... more
New Levitra® formulation submitted for registration in the EU
First orodispersible tablet for the treatment of erectile dysfunction more
Bayer robust in a difficult environment
HealthCare strong – further growth at CropScience – MaterialScience stabilized / Group sales EUR 8,009 million (minus 5.9 percent) / EBITDA before special items EUR 1,765 million (minus 6.9 percent)... more
Nexavar® in Combination with Chemotherapy Shown To Extend Progression-Free Survival in Patients with Advanced Breast Cancer
Statistically Significant Results Reported from a Phase II Study Combining Two Oral Cancer Therapies more
Bayer CropScience expands global R&D activities in seeds and traits by setting up new research focus area in cereals
Superior solutions for wheat farmers could be available as early as 2015 more
Bayer launches New Health Treatment for Dogs in China
Top parasite control for dogs becomes available for the first time more
Bayer presents positive Phase II data with florbetaben
Potential to visualize beta-Amyloid plaques in Patients with Alzheimer’s disease demonstrated / Florbetaben may innovate the diagnostic capabilities more
Bayer acquires exclusive rights to Bioton’s insulin SciLin®
Berlin, July 9th, 2009 – Bayer Schering Pharma AG, Germany, has signed an exclusive supply and distribution agreement with the Polish insulin producer Bioton S.A. and Bioton’s Singaporean subsidiary,... more
Bayer submits first-in-class estradiol-based oral contraceptive for approval in the U.S.
FDA approval requested for oral contraception and treatment of heavy and/or prolonged menstrual bleeding more
Bayer Animal Health launches all-in-one parasiticide for cats and dogs in Thailand
Comprehensive “spot-on” remedy against most common internal and external parasites more
Bayer CropScience and DuPont expand collaboration with broad license agreements
Monheim, Wilmington/Delaware, June 25, 2009 – Bayer CropScience and DuPont have entered into a series of long-term business agreements related to key plant biotechnology traits and enabling... more
Bayer Technology Services completed sulfuric acid plant featuring innovative technology
BAYQIK® process significantly reduces sulfur dioxide emissions and boosts production capacity cost-efficiently more
Bayer HealthCare and Genzyme Finalize Strategic Alliance Agreement
Berlin, Germany and Tarrytown, NY, USA, June 2, 2009 – Bayer HealthCare and Genzyme Corporation said today that they have received regulatory approvals for the strategic alliance announced on March... more
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Non-small Cell Lung Cancer
Berlin, June 1, 2009 – Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. today announced that the companies have begun enrolling patients in an international Phase III trial to evaluate Nexavar®... more
Bayer Schering Pharma Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Orlando, Florida, USA and Berlin, Germany, May 30, 2009 – Bayer Schering Pharma AG today announced results from Phase I and II trials of BAY 73-4506, a potent oral multi-kinase inhibitor currently... more
U.S. FDA Issues Complete Response Letter for Rivaroxaban
No new clinical or non-clinical studies to be conducted as a pre-requisite for approval more
Phase III Trial Started to Evaluate Combination Therapy of Nexavar® and Tarceva® in Patients with Liver Cancer
Berlin, May 28, 2009 – Bayer HealthCare AG, Onyx Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc. and Roche today announced the initiation of a Phase III trial examining Nexavar® (sorafenib) tablets... more
Bayer: Successful and sustainable business
Investment in the future: R&D budget of EUR 2.9 billion / Contributing solutions to global challenges: Global access to medicines, feeding the world population, water protection, climate change /... more
U.S. Department of Agriculture grants approval for Bayer CropScience’s GlyTol™ cotton technology
Monheim, May 22, 2009 – The U.S. Department of Agriculture (USDA) has granted approval for the GlyTol™ cotton technology developed by Bayer CropScience. Cotton varieties with the GlyTol™ trait are... more
Nexavar® Approved in Japan for the Treatment of Advanced Liver Cancer
Berlin, May 20, 2009 – Bayer received approval in Japan for Nexavar® (sorafenib) tablets for the treatment of unresectable hepatocellular carcinoma (HCC) from the Ministry of Health, Labour and... more
Bayer Schering Pharma presents positive results of phase II study with Riociguat
San Diego, USA / Berlin, Germany, May 19, 2009 – Positive data from a phase II trial with Bayer Schering Pharma’s oral agent riociguat (BAY 63-2521) in chronic thromboembolic pulmonary hypertension... more
Qlaira® – innovative estradiol-based oral contraceptive available in Europe from May onwards
A new oral contraceptive delivering the same estrogen as produced by the female body more
“Corporate strategy proves effective in a difficult environment”
Earnings targets met in 2008 / Proposed 3.7 percent increase in dividend, to EUR 1.40 per share / CropScience and Pharmaceuticals remain on a path of growth in the current year / Group targets... more
Bayer Schering Pharma is starting Phase III studies with an innovative low-dose contraceptive patch
Berlin, May 5, 2009 – Bayer Schering Pharma AG, Germany is starting Phase III with an innovative patch for female contraception that combines low dosed ethinylestradiol and gestodene. Approximately... more
Bayer HealthCare und Regeneron erweitern Entwicklungsprogramm von VEGF Trap-Eye
Neue Indikation: Zentralvenen-Verschluss des Auges / Start von zwei Phase-III-Studien in der zweiten Jahreshälfte 2009 more
CropScience and Pharmaceuticals continue on a path of growth – Slump in business at MaterialScience leaves a distinct mark
Group sales: EUR 7,895 million (minus 7.5 percent) / EBITDA before special items: EUR 1,695 million (minus 22.4 percent) / EBIT before special items: EUR 1,017 million (minus 32.1 percent) / Net cash... more
Bayer and Ardea Biosciences Enter Global Agreement Focused on the Development of MEK Inhibitors for the Treatment of Cancer
Berlin, April 28, 2009 – Bayer HealthCare AG, Germany has entered into a global agreement with Ardea Biosciences, Inc., San Diego California, USA (Nasdaq: RDEA) focused on the development of small... more
Phase III Trial of Nexavar® in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Study stopped based on interim analysis more
Bayer CropScience invests EUR 30 million in expansion of crop protection production at the Dormagen Chemical Park
Active substance Prothioconazole controls fungi that can harm human health more
Bayer CropScience has acquired certain AgroGreen´s biological products for the crop protection business
Monheim, March 31, 2009 – Bayer CropScience announced today that it acquired certain assets and technology related to biological development products of Agrogreen, Ashdod, Israel. Through this... more
Bayer HealthCare and Genzyme Corporation Enter New Strategic Agreement
Agreement improves profitability and strategic focus in key Bayer therapeutic areas / Licenses hematological cancer products to Genzyme / Continues co-development partnership for alemtuzumab in... more
Bayer MaterialScience builds new manufacturing facility for polyurethane raw materials in India
20 Million Euro investment underlines growth strategy in the region / New plant in Ankleshwar to produce Desmodur® polyisocyanates from 2011 more
Unprotected pets pose new health threat as world climate warms
Seville, Spain, March 26, 2009 – Leading experts in veterinary and human medicine, parasitology and meteorology gathered for the 4th Symposium of the CVBD (canine vector-borne disease) World Forum,... more
Energy efficiency expert Jochem wins “Bayer Climate Award”
Bayer foundation awards first international prize for climate research / Professor Jochem: Commercially profitable 80 percent boost in energy efficiency in the industrialized nations possible within... more
U.S. FDA Advisory Committee supports favorable benefit-risk profile of Bayer’s rivaroxaban
Leverkusen, March 19, 2009 – An Advisory Committee to the U.S. Food and Drug Administration (FDA) met today to discuss the new drug application (NDA) for Bayer’s rivaroxaban, a novel, oral... more
Bayer Animal Health announces regional co-operations on aquaculture and animal nutrition
Bangkok, March 12, 2009 – Bayer HealthCare’s Animal Health Division announced today that it is executing licensing agreements with four leading providers of aquaculture and animal nutrition products... more
Bayer: corporate strategy proves effective in a difficult environment
Sales increase by 1.6 percent to EUR 32,918 million / EBITDA before special items up 2.3 percent to EUR 6,931 million / EBIT before special items up 1.3 percent to EUR 4,342 million / Net income of... more
Bayer proposes increased dividend for 2008 of EUR 1.40 per share
Plans to switch from bearer shares to registered shares more
Bayer sponsors first Chair for Apparatus Engineering at Dortmund's Technical University
Rector Prof. Gather: "Entire spectrum in bio- and chemical engineering now covered" / Bayer Board member Dr. Plischke: "A further step in expanding our strategic networks with universities and... more
Bayer Schering Pharma to invest 100 million Euro in China to build a global R&D center
Berlin, February 12, 2009 – Bayer Schering Pharma AG, the pharmaceutical division of Bayer HealthCare (BHC), announced today that it will be strengthening its global Research and Development (R&D)... more
Bayer Schering Pharma Starts Phase III Program of New Drug Against Pulmonary Hypertension
Berlin, February 9, 2009 – Based on the positive findings from the clinical development phase II trial, Bayer Schering Pharma has begun a phase III program with its oral agent riociguat. Two phase... more
Bayer builds world's largest production plant for carbon nanotubes in Chempark Leverkusen
Construction start-up followed by kick-off event of the Innovationsallianz CNT in Leverkusen more
Visanne® - new long-term treatment for endometriosis submitted for registration in Europe
Bayer Schering Pharma AG, Germany, has submitted Visanne® for the treatment of endometriosis for registration to all Member States of the European Community. The Netherlands will serve as the... more
Bayer Strengthens Research and Development
Bayer innovations provide solutions for the global challenges of the future / Pharmaceutical pipeline is well filled, with 50 projects currently in phases I to III of clinical testing / Ten new crop... more
Xarelto® Reduces Symptomatic VTE and Death Following Knee or Hip Replacement Surgery by More Than 50% Compared to Enoxaparin in Pooled Analysis of RECORD Clinical Trial Program
Pooled Analysis of RECORD1-4 Trials Confirms Significant Benefit in Clinical Outcomes for Patients Treated with Xarelto / RECORD4 Study Demonstrates Xarelto is the Only Oral Anticoagulant to Show... more
Daniel Hartert to be new Executive Board Chairman of Bayer Business Services GmbH
Leverkusen, December 5, 2008 – Daniel Hartert (49) has been appointed Chairman of the Executive Board of Bayer Business Services GmbH (BBS) effective January 1, 2009. He succeeds Dr. Andreas Resch,... more
Bayer named best pharmaceutical and chemical company in Brazil
Sao Paulo / Leverkusen, November 13, 2008 – Bayer is recognized as Brazil’s best chemical and pharmaceutical company. This was the result of a survey of 12,000 consumers conducted by Época Negocios... more
Professor Berschauer: “Enabling a second green revolution in Asia with new, high-yielding rice varieties”
Rice seed production in Asia to be expanded substantially by 2017 more
Bayer’s Xarelto® Shows Encouraging Results in Patients with Acute Coronary Syndrome
Phase II Data Presented as Late-Breaker at American Heart Association Meeting / Phase III Study to be Initiated in December 2008 more
“Environmental Envoys” from 18 countries visit Bayer
Project part of partnership between the United Nations Environment Programme (UNEP) and Bayer more
Interim report for the third quarter of 2008: Bayer optimistic about future business trend
Sales rise by 2.0 percent to EUR 7,948 million (Q3 2007: EUR 7,793 million) / HealthCare and CropScience improve earning power / MaterialScience earnings significantly lower / Group EBITDA before... more
EUR 150,000 for scholarships and education of teachers
Funding for ambitious projects in ten countries / Focus on natural sciences and medicine more
Bayer significantly strengthens its presence in China
Startup of 350,000 tons/year MDI train / Groundbreaking for 250,000 tons/year TDI plant / Isocyanate production also to be expanded in Europe in the medium term more
First estradiol-based oral contraceptive Qlaira® cleared for market launch in Europe
A new oral contraceptive providing the same estrogen produced by the female body more
Bayer’s Novel Anticoagulant Xarelto® now also Approved in the EU
Bayer will start marketing the new oral, once-daily anticoagulant very soon / First-in-class product to demonstrate superior efficacy to current standard of care more
Bayer starts new research cooperation in Asia
Research collaboration with National University of Singapore signed / Further collaborations planned / Overall investment volume of 10 million Euro more
Squeeze-out entered in the Commercial Register
Squeeze-out of minority stockholders takes effect / Cash compensation of EUR 98.98 per share will be paid more
“We need a second green revolution”
The need to exploit all technological options for increasing yields more
Five year data confirm that early treatment with Betaferon® at first sign of disease can delay progression to MS
BENEFIT is first and only prospectively planned study to show long lasting benefit of early treatment more
Bayer MaterialScience LLC declares force majeure in the USA
Leverkusen/Baytown, September 19, 2008 – Bayer MaterialScience LLC, the North American subsidiary of Bayer MaterialScience AG, has declared force majeure for a large part of its production in... more
Bayer HealthCare acquires German DIREVO Biotech AG
A recognized leader in protein engineering / Expanding technological know-how in biologicals / Strengthening Bayer HealthCare’s commitment to develop innovative biologicals more
Bayer’s Xarelto® Approved in Canada
First approval for Bayer’s new oral, once-daily anticoagulant / Marketing to start immediately / First-in-class product to demonstrate superior efficacy to standard of care / Most studied oral,... more
The Search is on for the Best Pictures on the Subject of Climate Change
Winners are honored at an international event; attractive prizes to be won / More than 190,000 children from over 100 countries have submitted pictures since 1991 more
New low-dose oral contraceptive YAZ® launched in Europe
24/4 dosing regimen has shown to reduce hormone fluctuations more
Bayer CropScience plans investment of EUR 3.4 billion in research and development through 2012
Expansion of R&D program will strengthen basis for future growth / Achievement of target EBITDA margin of around 25 percent already expected in 2008 / Sales target of EUR 2 billion with new active... more
Otto Bayer Medals awarded for outstanding research
Three research teams from Bayer commended for innovations in healthcare, nutrition and high-tech materials / Bayer has the highest level of research and development spending in the German chemical... more
Sustainable help for earthquake-stricken college in Sichuan
Donation of 20 classrooms, 50 homes and a mobile clinic more
Bayer Submits Recombinant Human Thrombin for European Approval
Recothrom® would be the first recombinant human thrombin for use as a topical aid to surgical hemostasis in Europe more
Thiencarbazone-methyl registered in first market
Annual sales potential of more than EUR 100 million for new corn herbicide more
Bayer MaterialScience starts construction of a world-scale TDI plant in Shanghai
Annual capacity of 250,000 metric tons approved / Capacity can be increased to 300,000 metric tons per year / Start-up planned for 2010 more
Bayer HealthCare and Regeneron Announce VEGF Trap-Eye Achieved Durable Improvement in Vision over 52 Weeks in a Phase 2 Study in Patients with Age-related Macular Degeneration
Study patients, on average, received only two additional doses following a 12-week fixed dosing period more
Bayer’s Annual Report Receives International Praise
New York, August 12, 2008 – Praise all around for Bayer’s Annual Report 2007: It received gold, silver, bronze and honors twice each in the recently concluded Annual Report Competition (ARC). More... more
Bayer appoints Greg Babe as new CEO for U.S. Organisation
Predecessor Dr. Attila Molnar to retire more
Bayer continues its success
Sales up 3.6 percent to EUR 8,511 million / EBITDA before special items increases by 5.0 percent to EUR 1,896 million / EBIT before special items improves by 5.3 percent to EUR 1,248 million /... more
Bayer’s Novel Anticoagulant Rivaroxaban Submitted for Approval in the U.S.
Rivaroxaban is first oral anticoagulant to achieve superior efficacy over the twice-daily injection of enoxaparin while maintaining low rates of major bleeding / No evidence of safety issues... more
Nexavar Approved for Treatment of Liver Cancer in China
Nexavar is First Approved Systemic Therapy to Treat the Disease more
Bayer’s Novel Anticoagulant Rivaroxaban Recommended for Approval in the EU
Final approval from the European Commission expected within the next few months more
Andreas Fibig named new Chairman of the Board of Management of Bayer Schering Pharma
Dr. Bernd Metzner to become new Board member of Bayer’s pharmaceuticals subsidiary / Arthur Higgins and Werner Baumann to refocus on their leadership roles in the Bayer HealthCare subgroup following... more
Tembotrione from Bayer CropScience approved in Brazil
Launch of Soberan® planned for 2008 more
Primovist® approved in the U.S. for the Detection and Characterization of Liver Lesions
Berlin, July 8, 2008 – The U.S. Food and Drug Administration (FDA) has approved Bayer Schering Pharma’s magnetic resonance imaging (MRI) contrast agent Primovist® (gadoxetate disodium) for the... more
Bayer HealthCare Completes Acquisition of Western OTC Cough and Cold Business of Topsun Science and Technology
Significantly Strengthens Consumer Care Division’s Business in High Growth Chinese OTC Market more
Bayer HealthCare acquires hematology development portfolio featuring MAXY-VII from Maxygen
Phase 1 clinical testing expected to commence in third quarter of 2008 / Transaction includes license to Maxygen’s novel biotechnology research platform more
Bayer concludes supply and licensing agreements for Yasmin® and YAZ® with Barr for the United States
Appeal of court decision invalidating Yasmin patent will continue / Further growth of Bayer’s Women’s Healthcare Business Unit expected more
Bayer receives Environmental Award from the Federation of German Industries
Energy-efficient process recycles chlorine from hydrochloric acid / Industrial application in Germany and China / Bayer Management Board member Dr. Plischke: “Increase in energy efficiency brings... more
Bayer plans to invest EUR 100 million in Brazil
Wenning: “Brazil is our biggest market in Latin America” more
Bayer CEO Werner Wenning receives prestigious McCloy Award
Former German Foreign Minister Hans-Dietrich Genscher presents the honor in New York more
Bayer will use tobacco plants to produce medicines
First development candidate from the new plant for cancer indication non-Hodgkin’s lymphoma – Clinical phase I could start in 2009 / Bayer has invested over EUR 10 million in Halle since 2006 more
Bayer Climate Program makes great advances
Climate protection projects rigorously implemented / Commitment to global health care provision / EUR 45 million spent annually to support 300 social projects worldwide / EUR 500,000 per year alone... more
Bayer HealthCare successfully completes acquisition of Sagmel, Inc.’s OTC Business
Bayer Consumer Care’s Presence in Eastern Europe Significantly Strengthened more
Bayer increases aid to disaster victims in China and Burma
Cash and material donations now stand at more than EUR 1.4 million more
Rivaroxaban One Tablet/Once-Daily Superior to Twice-Daily Injectable Enoxaparin in Preventing Venous Blood Clots after Total Knee Replacement Surgery in Pivotal Phase III Trial
Rivaroxaban is First Oral Anticoagulant to Achieve Superior Efficacy over the Twice-Daily Injection of Enoxaparin while Maintaining Low Major Bleeding Rates / RECORD4 Confirms Results of RECORD1, 2... more
Nexavar Significantly Extends Overall Survival in Liver Cancer
Trial Results Confirm Efficacy for Population Most Affected by the Disease more
Bayer to Help Victims of Natural Disasters in China and Burma
Goods and Funds Donation in the Amount of 350,000 Euros more
Bayer lays the foundation for its zero-emission building in India
The “EcoCommercial Building” concept saves 70 percent of electrical energy / Chairman of the Bayer Board of Management Werner Wenning: “A milestone in the Bayer Climate Program” / More buildings to... more
Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye in Wet Age-related Macular Degeneration
International study to evaluate efficacy and safety in treating a leading cause of blindness more
Bayer Schering Pharma to market new low-dose oral contraceptive YAZ® in Europe
Berlin, May 6, 2008 – Bayer Schering Pharma’s new low-dose oral contraceptive YAZ® has been approved in the EU.YAZ® will be the first oral contraceptive on the European market containing the unique... more
“2007 was Bayer’s most successful year to date”
Previous year’s record levels and earnings targets exceeded / Dividend to be raised 35 percent to EUR 1.35 / Good start to fiscal 2008 / Bayer Climate Program being implemented and expanded more
Bayer off to an excellent start in 2008
Sales up 2.4 percent to EUR 8,536 million / EBITDA before special items up 9.8 percent to EUR 2,185 million / EBIT before special items up 8.9 percent to EUR 1,497 million / Full-year guidance for... more
Bayer Challenges Watson and Sandoz U.S. ANDA Filings on Yasmin®
Leverkusen, April 21, 2008 – Bayer confirmed that Bayer Schering Pharma AG and Bayer HealthCare Pharmaceuticals Inc. filed a patent infringement lawsuit in U.S. Federal Court in the Southern District... more
Bayer donates €250,000 for patients with hemophilia and provides nearly 1 million international units of Kogenate®
World Hemophilia Day on April 17th more
Bayer HealthCare Affiliate MEDRAD Announces Completion of Subsequent Offering Period for Shares of Possis Medical
Merger to Be Completed Shortly more
Bayer appeals invalidity ruling on its Yasmin® Patent
Appeal will be heard by the Federal Circuit more
Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement
Leverkusen, Germany, / Minneapolis, MN, USA – Bayer HealthCare affiliate MEDRAD, Inc., Warrendale, PA and Possis Medical, Inc., Minneapolis, MN, (Nasdaq: POSS), announced today that they have entered... more
Nexavar® Approved for the Treatment of Kidney Cancer in Japan
First approved oral targeted therapy for metastatic RCC in Japan more
Bayer extends product portfolio for liver cancer patients in Japan
Japanese authorities grant priority review status for Nexavar® in liver cancer / Launch of liver-specific contrast agent Primovist® in Japan more
Bayer establishes US special access program for Leukine® while replacing current liquid formulation
Leukine lyophilized formulation temporarily reserved for patients with Acute Myelogenous Leukemia (AML) and those experiencing bone marrow transplantation graft failure or engraftment delay / Bayer... more
US Food and Drug Administration Approves RECOTHROM™
Leverkusen – Bayer HealthCare announced today that its partner, ZymoGenetics Inc., received US Food and Drug Administration (FDA) approval of RECOTHROM™ Thrombin, topical (recombinant) for use as a... more
Archer Daniels Midland Company, Bayer CropScience and Daimler to cooperate in Jatropha biodiesel project
A new high-potential biofuel crop more
Expanded Labeling for MabCampath® in Europe
B-cell chronic lymphocytic leukemia (B-CLL): more